NCT06754098 - Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

December 31, 2027

Conditions

Thymidine Kinase 2 (TK2 ) DeficiencyMitochondrial Myopathies

Interventions

DRUG

Doxecitine and Doxribtimine

A combination of doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart .Dose will be increased if the tolerability profile is good.

Trial Locations (1)

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid